Anti-relapse therapy of endometriosis: possible variations

Research aim: to determine the clinical efficacy and safety of bioavailable curcumin Longimin® in complex anti-relapse therapy patients with extragenital endometriosis after surgery.Materials methods. Study involved 45 women a mean age 29.3 ± 3.6 years diagnosis endometriosis. After surgical treatment this disease all were prescribed dienogest 2 mg/day for 6 months purpose. that, 22 did not receive drug (group 1) other 23 started six-month course 400 mg 2).Results. 12 observation 3 cases (13.6%) newly formed foci found among group 1, two which multi-endometriomas, third was retrocervical heterotopia. There no signs recurrence sequential use curcumin. In addition, completion hormonal number chronic pelvic pain 1 increased average score on visual analogue scale (VAS) by 80% (p ≤0.05). It accompanied stable moderately high level anxiety throughout period. At same time who complained intermenstrual decreased from 15 13, VAS 13% ≥0.05) during Patients noted an improvement emotional control treatment, resulted decrease personal situational Spielberg-Hanin's questionnaire (25% 30% respectively, p ≤0.05).Conclusions. The nature development progression is multipathogenetic. Blocking only its link, especially forms, may be sufficient stop pathological process prevent long term. Оbtained results purpose showed wider effectiveness therapy, probably based additional inhibition systemic inflammation, proliferation, stroma psychogenic component disease.